Patent application number | Description | Published |
20080241114 | Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or T cell subset activity by modulation of XBP-1 activity - The invention demonstrates that the transcription factor XBP-1 is a regulator of hepatocyte growth, plasma cell differentiation and T cell subset activity. Methods for identifying modulators of hepatocyte growth, plasma cell differentiation and/or T cell subset activity, using XBP-1-containing indicator compositions or XBP-1-deficient cells, are provided. Methods of modulating hepatocyte growth, plasma cell differentiation and/or T cell subset activity (e.g., Th2 cytokine production) using agents that modulate the activity of XBP-1 are also provided. Methods for diagnosing disorders associated with aberrant hepatocyte growth, plasma cell differentiation and/or T cell subset activity, by assessing a change in XBP-1 expression, are also provided. XBP-1 deficient cells, animals and embryos, as well as kits for the methods of the invention, are also provided by the invention. | 10-02-2008 |
20080300384 | T-bet compositions and methods of use thereof - Isolated nucleic acid molecules encoding T-bet, and isolated T-bet proteins, are provided. The invention further provides antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals carrying a T-bet transgene. The invention further provides T-bet fusion proteins and anti-T-bet antibodies. Methods of using the T-bet compositions of the invention are also disclosed, including methods for detecting T-bet activity in a biological sample, methods of modulating T-bet activity in a cell, and methods for identifying agents that modulate the activity of T-bet. | 12-04-2008 |
20080318987 | METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION - Methods and compositions for modulating bone formation and mineralization are described. | 12-25-2008 |
20090048117 | MODULATION OF IMMUNE SYSTEM FUNCTION BY MODULATION OF POLYPEPTIDE ARGININE METHYLTRANSFERASES - The instant invention pertains to, e.g., method of identifying a compound that modulates cytokine production or T cell receptor-mediated signaling, by identifying modulators of the expression and/or activity or PRMT polypeptides. The invention further pertains to methods for identifying a compound that modulates cytokine production in a non-T cell, by identifying compounds that modulate the expression and/or activity of NIP45. Methods for modulating cytokine production in cells by modulating the expression and/or activity of at least one molecule selected from the group consisting of: NIP45, PRMT1, and NFAT are also provided. The invention also pertains to methods for modulating the relative number of Th1 or Th2 cells is modulated and to methods of treating a subject that would benefit from the modulation of cytokine production comprising contacting an immune cell from the subject with an agent that modulates PRMT 1 expression and/or activity in the immune cell. | 02-19-2009 |
20090053189 | Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof - The present invention is based, at least in part, on the identification of molecules involved in the differentiation and/or activity of osteoblasts and osteoclasts. Accordingly, the present invention provides methods of identifying modulators of bone formation, mineralization, and/or osteoclastogenesis and methods for treating disorders that would benefit from modulation of bone formation, mineralization, and/or osteoclastogenesis using agents identified as described herein. | 02-26-2009 |
20090060902 | Methods and compositions for regulating T cell subsets by modulating transcription factor activity - Methods for modulating production of a T helper type 2 (Th | 03-05-2009 |
20090232738 | Methods for modulating de novo hepatic lipogenesis by modulating XBP-1 activity - The invention provides methods and compositions for modulating the expression, processing, post-translational modification, stability and/or activity of XBP-1 protein, or a protein in a signal transduction pathway involving XBP-1 to treat dyslipidemias and steatosis disorders. The present invention also pertains to methods for identifying compounds that modulate the expression, processing, post-translational modification, and/or activity of XBP-1 protein or a molecule in a signal transduction pathway involving XBP-1. | 09-17-2009 |
20090298091 | Modulation of T Cell Recruitment - The instant invention is based, at least in part, on the discovery that T-bet controls ThI cell recruitment to sites of inflammation. This invention pertains to, inter alia, methods of identifying agents that modulate the effects of T-bet on the recruitment of T cells to sites of inflammation by modulating P-selectin-mediated T cell rolling and/or stable adherence of a T cell to a vascular endothelial cell, as well as methods of use therefore. | 12-03-2009 |
20090318338 | METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION BY MODULATING KRC ACTIVITY - This invention demonstrates that KRC molecules have multiple important functions as modulating agents in regulating a wide variety of cellular processes including bone formation and mineralization. TGF-β signaling in osteoblasts promotes the formation of a multimeric complex between KRC, Runx2, Smad3, and the E3 ubiquitin ligase, WWP1 which inhibits Runx2 function due to the ability of WWP1 to promote Runx2 polyubiquitination and proteasome-dependent degradation. Furthermore, KRC and WWP1 form a complex with RSK2 which promotes RSK2 phosphorylation and inhibits RSK2 function due to the ability of WWP 1 to promote RSK2 ubiquitination. Methods for identifying modulators of KRC activity are provided. Methods for modulating an immune response, bone formation and mineralization, and KRC-associated disorders using agents that modulate KRC expression and/or activity are also provided. | 12-24-2009 |
20100183514 | MOLECULES INVOLVED IN REGULATION OF OSTEOBLAST ACTIVITY AND OSTEOCLAST ACTIVITY, AND METHODS OF USE THEREOF - The present invention is based, at least in part, on the identification of molecules involved in the differentiation and/or activity of osteoblasts and osteoclasts. Accordingly, the present invention provides methods of identifying modulators of bone formation, mineralization, and/or osteoclastogenesis and methods for treating disorders that would benefit from modulation of bone formation, mineralization, and/or osteoclastogenesis using agents identified as described herein. The target biomolecules of these methods are, for example, the osteoblast regulators TA0K2 or DLG1 or P1N1 or LYK5 or M0BKL2C or MAP4K2 or PACSIN2 or DCAMKLI or D0CK4 or PARO1 or TA0K3 or TRPV6 or CLK1 or AAK1 or PRKCA or AKAP8 or DGKJ or SMARCB1 or CIB2 or STIK33 or STK 39 or NRGN or PIK3R1 or RASSF5 or FRAPI or STK3S or LATSI or LATS2 or STK38L or GEFT or TNNI3K or STK4 or RAF1 or ARFI or CI7orf1 or SMURF2. The assays may involve mesenchymal cells. Also screening assays using osteoclast regulators such as GCK or WASH or PPP2CB or PPP2R1A or CREBBP or CUL3 or FBXW1 or MELK or PLCLI or MAP3K3 or DLGH1 or NEK7 or JIRAK3 or RHOC or SLC4A2 or PLCB4 or B-RAF or BMPR2 or MAPK3 or NHEDC2 are proposed, e.g. using hemapoietic stem cell assays. | 07-22-2010 |
20100204053 | ASSAYS FOR THE IDENTIFICATION OF COMPOUNDS THAT MODULATE BONE FORMATION AND MINERALIZATION - This invention demonstrates that KRC molecules have multiple important functions as modulating agents in regulating a wide variety of cellular processes including bone formation and mineralization. TGF-β signaling in osteoblasts promotes the formation of a multimeric complex between KRC, Runx2, Smad3, and the E3 ubiquitin ligase, WWP1 which inhibits Runx2 function due to the ability of WWP1 to promote Runx2 polyubiquitination and proteasome-dependent degradation. Furthermore, KRC and WWP1 form a complex with RSK2 which inhibits RS K2 function due to the ability of WWP1 to promote RSK2 ubiquitination. Methods for identifying modulators of KRC activity are provided. Methods for modulating an immune response, bone formation and mineralization and KRC-associated disorders using agents that modulate KRC expression and/or activity are also provided. | 08-12-2010 |
20100242124 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF ULCERATIVE COLITIS AND COLON CANCER AND SCREENING METHODS TO IDENTIFY SAME - The instant invention is based, at least in part, on the discovery that T-bet maintains host commensal relationships in the gastrointestinal tract. Accordingly, this invention provides methods of treating and/or preventing ulcerative colitis, and/or colon cancer, and/or preventing colonization of a subject's gastrointestinal tract with commensal bacteria that promote ulcerative colitis as well as methods of identifying agents that treat and prevent the same. | 09-23-2010 |
20110052669 | METHODS FOR MODULATING DE NOVO HEPATIC LIPOGENESIS BY MODULATING XBP-1 ACTIVITY - The invention provides methods and compositions for modulating the expression, processing, post-translational modification, stability and/or activity of XBP-1 protein, or a protein in a signal transduction pathway involving XBP-I to treat dyslipidemias and steatosis disorders. The present invention also pertains to methods for identifying compounds that modulate the expression, processing, post-translational modification, and/or activity of XBP-I protein or a molecule in a signal transduction pathway involving XBP-1. | 03-03-2011 |
20110142799 | MODULATION OF NEURODEGENERATIVE DISEASE BY MODULATING XBP-1 ACTIVITY - The invention provides methods for treating and preventing a neurodegenerative disease associated with aberrant protein aggregation by modulating the expression and/or activity of XBP-1, IRE-1 alpha, and/or EDEM. The present invention also pertains to methods for identifying compounds that modulate the expression and/or activity of XBP-1, 1RE-1 alpha, and/or EDEM. The present invention further provides methods for determining whether a subject is at risk of developing or has developed a neurodegenerative disease associated with aberrant protein aggregation. | 06-16-2011 |
20120141539 | METHODS FOR MODULATING TOLL-LIKE RECEPTOR MEDIATED ACTIVATION OF CELLS OF THE INNATE SYSTEM BY MODULATING XBP-1 ACTIVITY - The invention provides methods and compositions for modulating the activity of XBP-I protein, or a protein in a signal transduction pathway involving XBP-I to modulate the TLR-mediated activation of cells of the innate immune system. Enhancing the TLR-mediated activation of cells of the innate immune system enhance inflammatory responses. The present invention also pertains to methods for identifying compounds that modulate Toll-like receptor-mediated signaling. | 06-07-2012 |
20120159661 | T-Bet Compositions and Methods of Use Thereof - Isolated nucleic acid molecules encoding T-bet, and isolated T-bet polypeptides, are provided. The invention further provides antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals carrying a T-bet transgene. The invention further provides T-bet fusion proteins and anti-T-bet antibodies. Methods of using the T-bet compositions of the invention are also disclosed, including methods for detecting T-bet expression and/or activity in a biological sample, methods of modulating T-bet expression and/or activity in a cell, and methods for identifying agents that modulate the expression and/or activity of T-bet. | 06-21-2012 |